COVID-19 Resources and Projects

Across UC Berkeley, researchers have redirected their investigations to address the challenges of the COVID-19 crisis. Learn about all the ways our experts are offering solutions across disciplines. Photo: The UC Berkeley COVID-19 test processing center. Courtesy of Max & Jules Photography.

 

The Office of Intellectual Property and Industry Research Alliances is seeking partners and resources to accelerate UC Berkeley’s extraordinary, communal efforts to understand and mitigate the impacts of the new coronavirus. Below, you'll find special licensing resources to incentivize rapid utilization of UC Berkeley technologies related to COVID-19, as well as examples of how UC Berkeley is partnering with industry to mitigate this pandemic.

 

Please contact IPIRA for information related to:

  • • Intellectual Property Licensing
  • • Receiving and Sending Materials and Data
  • • Corporate Sponsored Research
  • • Entrepreneurship

 

For campus policies and resources related to COVID-19, incuding health and safety information, see UC Berkeley's response to the coronavirus outbreak and find guidance on research operations and continuity planning.

Special Intellectual Property Licensing

 

Industry and academia are collaborating with unprecedented urgency to develop technological solutions in the global fight against the COVID-19 outbreak. UC Berkeley has developed a non-exclusive, royalty-free license template to induce commercial investment in research, development, and commercialization of COVID-19-related life-saving therapeutics and tools.

Corporate Partnerships Addressing COVID-19

 

The University of California, Berkeley, and the University of Illinois at Urbana-Champaign (UIUC) are the headquarters of a bold new research consortium established by enterprise AI software company C3.ai to leverage the convergence of artificial intelligence (AI), machine learning and the internet of things (IoT) to transform societal-scale systems. The c3.ai DTI currently has an open call for proposals for AI techniques to mitigate the COVID-19 pandemic. Researchers are encouraged to develop proposals that enhance or utilize the recently published C3.ai COVID-19 Data Lake. an aggregation of diverse structured and unstructured data sets.

The Laboratory for Genomics Research is a collaboration between GlaxoSmithKline and the Innovative Genomics Institute, bringing together academic and industrial researchers to accelerate the application of state-of-the-art CRISPR gene-editing techniques. The LGR has funded ten projects at UC Berkeley and UCSF that will rapidly address COVID-19. Each Excellence in Research Award provides approximately $100,000 in seed funding.

 

 

JOIN OUR MAILING LIST